Loading...
Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Jeremy Rich

    TitleAssociate Physician Diplomate
    SchoolUniversity of California, San Diego
    DepartmentMedicine
    Address9500 Gilman Drive #0695
    CA La Jolla 92093
    Phone858-822-2703
    vCardDownload vCard

      Collapse Biography 
      Collapse Education and Training
      Duke University School of Medicine, Durham, NCMHS05/2009Clinical Research Training Program
      Baldwin Wallace University, Parma, OHMBA05/2016Health Care
      Duke University Medical Center, Durham, NC06/1998Neuro-Oncology
      Johns Hopkins Hospital, Baltimore, MD06/1997Neurology
      Johns Hopkins Hospital, Baltimore, MD06/1994Internal Medicine
      Duke University School of Medicine, Durham, NCMD05/1993Medicine
      Washington University, St. Louis, MOB.S.05/1989Electrical Engineering

      Collapse Research 
      Collapse Research Activities and Funding
      Dynamic Complexity of Brain Tumor Stem Cells
      NIH/NCI R35CA197718Aug 1, 2015 - Aug 31, 2022
      Role: Principal Investigator
      Instructive Cues in Glioblastoma Hierarchies
      NIH/NCI R01CA171652Aug 15, 2014 - Jul 31, 2019
      Role: Principal Investigator
      Energy Stress in Brain Tumor Initiating Stem Cells
      NIH/NINDS R01NS089272Aug 1, 2014 - Jul 31, 2019
      Role: Principal Investigator
      Metabolism Informs Intertumoral & Intratumoral Heterogeneity
      NIH/NINDS R01NS087913Apr 15, 2014 - Feb 28, 2019
      Role: Co-Principal Investigator
      Targeting Ferritin in Glioblastoma
      NIH/NCI R01CA169117Jul 1, 2013 - Apr 30, 2018
      Role: Co-Principal Investigator
      Targeting Brain Tumor Stem Cells Through Novel Therapeutic Combinations
      NIH/NCI R01CA154130Jul 1, 2010 - Dec 31, 2014
      Role: Principal Investigator
      Stem Cell-Like Glioma Cells in Angiogenesis
      NIH/NCI R01CA129958Apr 7, 2008 - Dec 31, 2013
      Role: Principal Investigator
      TGFbeta-PTEN Interactions in Glioma Biology &Therapy
      NIH/NCI R01CA116659Aug 1, 2006 - Dec 31, 2011
      Role: Principal Investigator
      Molecular Mechanisms of SPARC Mediated Glioma Invasion
      NIH/NINDS R01NS054276Feb 15, 2006 - Jan 31, 2011
      Role: Principal Investigator
      The Roles of Osteonectin and Osteoactivin in Gliomas
      NIH/NINDS K02NS047409Jun 1, 2004 - Feb 28, 2009
      Role: Principal Investigator
      TGF beta and Brain Tumors
      NIH/NINDS K08NS002055Jul 1, 1998 - Jun 30, 2003
      Role: Principal Investigator

      Collapse ORNG Applications 
      Collapse Featured Publications

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Zhu Z, Gorman MJ, McKenzie LD, Chai JN, Hubert CG, Prager BC, Fernandez E, Richner JM, Zhang R, Shan C, Tycksen E, Wang X, Shi PY, Diamond MS, Rich J, Chheda MG. Correction: Zika virus has oncolytic activity against glioblastoma stem cells. J Exp Med. 2017 Sep 15. PMID: 28916645.
        View in: PubMed
      2. Zhu Z, Gorman MJ, McKenzie LD, Chai JN, Hubert CG, Prager BC, Fernandez E, Richner JM, Zhang R, Shan C, Wang X, Shi PY, Diamond MS, Rich J, Chheda MG. Zika virus has oncolytic activity against glioblastoma stem cells. J Exp Med. 2017 Sep 05. PMID: 28874392.
        View in: PubMed
      3. Rosager AM, Sørensen MD, Dahlrot RH, Hansen S, Schonberg DL, Rich J, Lathia JD, Kristensen BW. Transferrin receptor-1 and ferritin heavy and light chains in astrocytic brain tumors: Expression and prognostic value. PLoS One. 2017; 12(8):e0182954. PMID: 28837569.
        View in: PubMed
      4. Wang X, Huang Z, Wu Q, Prager BC, Mack SC, Yang K, Kim LJY, Gimple RC, Shi Y, Lai S, Xie Q, Miller TE, Hubert CG, Song A, Dong Z, Zhou W, Fang X, Zhu Z, Mahadev V, Bao S, Rich J. MYC-Regulated Mevalonate Metabolism Maintains Brain Tumor-Initiating Cells. Cancer Res. 2017 Jul 20. PMID: 28729418.
        View in: PubMed
      5. Perera VS, Covarrubias G, Lorkowski M, Atukorale P, Rao A, Raghunathan S, Gopalakrishnan R, Erokwu BO, Liu Y, Dixit D, Brady-Kalnay SM, Wilson D, Flask C, Rich J, Peiris PM, Karathanasis E. One-pot synthesis of nanochain particles for targeting brain tumors. Nanoscale. 2017 Jul 13; 9(27):9659-9667. PMID: 28675230.
        View in: PubMed
      6. Miller TE, Liau BB, Wallace LC, Morton AR, Xie Q, Dixit D, Factor DC, Kim LJY, Morrow JJ, Wu Q, Mack SC, Hubert CG, Gillespie SM, Flavahan WA, Hoffmann T, Thummalapalli R, Hemann MT, Paddison PJ, Horbinski CM, Zuber J, Scacheri PC, Bernstein BE, Tesar PJ, Rich J. Transcription elongation factors represent in vivo cancer dependencies in glioblastoma. Nature. 2017 Jul 20; 547(7663):355-359. PMID: 28678782.
        View in: PubMed
      7. Shi Y, Ping YF, Zhou W, He ZC, Chen C, Bian BS, Zhang L, Chen L, Lan X, Zhang XC, Zhou K, Liu Q, Long H, Fu TW, Zhang XN, Cao MF, Huang Z, Fang X, Wang X, Feng H, Yao XH, Yu SC, Cui YH, Zhang X, Rich J, Bao S, Bian XW. Tumour-associated macrophages secrete pleiotrophin to promote PTPRZ1 signalling in glioblastoma stem cells for tumour growth. Nat Commun. 2017 Jun 01; 8:15080. PMID: 28569747.
        View in: PubMed
      8. Soeda A, Lathia J, Williams BJ, Wu Q, Gallagher J, Androutsellis-Theotokis A, Giles AJ, Yang C, Zhuang Z, Gilbert MR, Rich J, Park DM. The p38 signaling pathway mediates quiescence of glioma stem cells by regulating epidermal growth factor receptor trafficking. Oncotarget. 2017 May 16; 8(20):33316-33328. PMID: 28410196.
        View in: PubMed
      9. Dixit D, Xie Q, Rich J, Zhao JC. Messenger RNA Methylation Regulates Glioblastoma Tumorigenesis. Cancer Cell. 2017 04 10; 31(4):474-475. PMID: 28399407.
        View in: PubMed
      10. Fang X, Zhou W, Wu Q, Huang Z, Shi Y, Yang K, Chen C, Xie Q, Mack SC, Wang X, Carcaboso AM, Sloan AE, Ouyang G, McLendon RE, Bian XW, Rich J, Bao S. Deubiquitinase USP13 maintains glioblastoma stem cells by antagonizing FBXL14-mediated Myc ubiquitination. J Exp Med. 2017 Jan; 214(1):245-267. PMID: 27923907.
        View in: PubMed
      11. Shi Y, Zhou W, Cheng L, Chen C, Huang Z, Fang X, Wu Q, He Z, Xu S, Lathia JD, Ping Y, Rich J, Bian XW, Bao S. Tetraspanin CD9 stabilizes gp130 by preventing its ubiquitin-dependent lysosomal degradation to promote STAT3 activation in glioma stem cells. Cell Death Differ. 2017 Jan; 24(1):167-180. PMID: 27740621.
        View in: PubMed
      12. Rich J. Cancer stem cells: master gatekeepers and regulators of cancer growth and metastasis Introduction. Medicine (Baltimore). 2016 Sep; 95(1 Suppl 1):S1. PMID: 27611933.
        View in: PubMed
      13. Rich J. Cancer stem cells: understanding tumor hierarchy and heterogeneity. Medicine (Baltimore). 2016 Sep; 95(1 Suppl 1):S2-7. PMID: 27611934.
        View in: PubMed
      14. Rich J, Matsui WH, Chang JC. Cancer stem cells: A nuanced perspective. Medicine (Baltimore). 2016 Sep; 95(1 Suppl 1):S26-8. PMID: 27611936.
        View in: PubMed
      15. Jin X, Jeon HM, Jin X, Kim EJ, Yin J, Jeon HY, Sohn YW, Oh SY, Kim JK, Kim SH, Jung JE, Kwak S, Tang KF, Xu Y, Rich J, Kim H. The ID1-CULLIN3 Axis Regulates Intracellular SHH and WNT Signaling in Glioblastoma Stem Cells. Cell Rep. 2016 Aug 09; 16(6):1629-1641. PMID: 27477274.
        View in: PubMed
      16. Burgett ME, Lathia JD, Roth P, Nowacki AS, Galileo DS, Pugacheva E, Huang P, Vasanji A, Li M, Byzova T, Mikkelsen T, Bao S, Rich J, Weller M, Gladson CL. Direct contact with perivascular tumor cells enhances integrin avß3 signaling and migration of endothelial cells. Oncotarget. 2016 Jul 12; 7(28):43852-43867. PMID: 27270311.
        View in: PubMed
      17. Xie Q, Wu Q, Kim L, Miller TE, Liau BB, Mack SC, Yang K, Factor DC, Fang X, Huang Z, Zhou W, Alazem K, Wang X, Bernstein BE, Bao S, Rich J. RBPJ maintains brain tumor-initiating cells through CDK9-mediated transcriptional elongation. J Clin Invest. 2016 Jul 01; 126(7):2757-72. PMID: 27322055; PMCID: PMC4922685 [Available on 10/01/16].
      18. Otvos B, Silver DJ, Mulkearns-Hubert EE, Alvarado AG, Turaga SM, Sorensen MD, Rayman P, Flavahan WA, Hale JS, Stoltz K, Sinyuk M, Wu Q, Jarrar A, Kim SH, Fox PL, Nakano I, Rich J, Ransohoff RM, Finke J, Kristensen BW, Vogelbaum MA, Lathia JD. Cancer Stem Cell-Secreted Macrophage Migration Inhibitory Factor Stimulates Myeloid Derived Suppressor Cell Function and Facilitates Glioblastoma Immune Evasion. Stem Cells. 2016 Aug; 34(8):2026-39. PMID: 27145382.
        View in: PubMed
      19. Godek KM, Venere M, Wu Q, Mills KD, Hickey WF, Rich J, Compton DA. Chromosomal Instability Affects the Tumorigenicity of Glioblastoma Tumor-Initiating Cells. Cancer Discov. 2016 05; 6(5):532-45. PMID: 27001151; PMCID: PMC4854766 [Available on 05/01/17].
      20. Dermawan JK, Hitomi M, Silver DJ, Wu Q, Sandlesh P, Sloan AE, Purmal AA, Gurova KV, Rich J, Lathia JD, Stark GR, Venere M. Pharmacological Targeting of the Histone Chaperone Complex FACT Preferentially Eliminates Glioblastoma Stem Cells and Prolongs Survival in Preclinical Models. Cancer Res. 2016 04 15; 76(8):2432-42. PMID: 26921329; PMCID: PMC4873320 [Available on 04/15/17].
      21. Mack SC, Hubert CG, Miller TE, Taylor MD, Rich J. An epigenetic gateway to brain tumor cell identity. Nat Neurosci. 2016 Jan; 19(1):10-9. PMID: 26713744.
        View in: PubMed
      22. Gallo M, Coutinho FJ, Vanner RJ, Gayden T, Mack SC, Murison A, Remke M, Li R, Takayama N, Desai K, Lee L, Lan X, Park NI, Barsyte-Lovejoy D, Smil D, Sturm D, Kushida MM, Head R, Cusimano MD, Bernstein M, Clarke ID, Dick JE, Pfister SM, Rich J, Arrowsmith CH, Taylor MD, Jabado N, Bazett-Jones DP, Lupien M, Dirks PB. MLL5 Orchestrates a Cancer Self-Renewal State by Repressing the Histone Variant H3.3 and Globally Reorganizing Chromatin. Cancer Cell. 2015 Dec 14; 28(6):715-729. PMID: 26626085.
        View in: PubMed
      23. Rich J. Lending an 'ELPing hand to tumor initiation. J Exp Med. 2015 Nov 16; 212(12):1989. PMID: 26573584; PMCID: PMC4647271.
      24. Zhou W, Cheng L, Shi Y, Ke SQ, Huang Z, Fang X, Chu CW, Xie Q, Bian XW, Rich J, Bao S. Arsenic trioxide disrupts glioma stem cells via promoting PML degradation to inhibit tumor growth. Oncotarget. 2015 Nov 10; 6(35):37300-15. PMID: 26510911; PMCID: PMC4741931.
      25. Schonberg DL, Miller TE, Wu Q, Flavahan WA, Das NK, Hale JS, Hubert CG, Mack SC, Jarrar AM, Karl RT, Rosager AM, Nixon AM, Tesar PJ, Hamerlik P, Kristensen BW, Horbinski C, Connor JR, Fox PL, Lathia JD, Rich J. Preferential Iron Trafficking Characterizes Glioblastoma Stem-like Cells. Cancer Cell. 2015 Oct 12; 28(4):441-455. PMID: 26461092; PMCID: PMC4646058 [Available on 10/12/16].
      26. Mack SC, Rich J, Scacheri PC. "PEAR-ing" Genomic and Epigenomic Analyses for Cancer Gene Discovery. Cancer Discov. 2015 Oct; 5(10):1018-20. PMID: 26429935; PMCID: PMC4608252.
      27. Alvarado AG, Turaga SM, Sathyan P, Mulkearns-Hubert EE, Otvos B, Silver DJ, Hale JS, Flavahan WA, Zinn PO, Sinyuk M, Li M, Guda MR, Velpula KK, Tsung AJ, Nakano I, Vogelbaum MA, Majumder S, Rich J, Lathia JD. Coordination of self-renewal in glioblastoma by integration of adhesion and microRNA signaling. Neuro Oncol. 2016 May; 18(5):656-66. PMID: 26374689; PMCID: PMC4827035 [Available on 05/01/17].
      28. Venere M, Horbinski C, Crish JF, Jin X, Vasanji A, Major J, Burrows AC, Chang C, Prokop J, Wu Q, Sims PA, Canoll P, Summers MK, Rosenfeld SS, Rich J. The mitotic kinesin KIF11 is a driver of invasion, proliferation, and self-renewal in glioblastoma. Sci Transl Med. 2015 Sep 09; 7(304):304ra143. PMID: 26355032; PMCID: PMC4743764.
      29. Lathia JD, Mack SC, Mulkearns-Hubert EE, Valentim CL, Rich J. Cancer stem cells in glioblastoma. Genes Dev. 2015 Jun 15; 29(12):1203-17. PMID: 26109046; PMCID: PMC4495393.
      30. Xie Q, Wu Q, Mack SC, Yang K, Kim L, Hubert CG, Flavahan WA, Chu C, Bao S, Rich J. CDC20 maintains tumor initiating cells. Oncotarget. 2015 May 30; 6(15):13241-54. PMID: 25938542; PMCID: PMC4537011.
      31. Ahluwalia MS, Rich J. Growth Factor Receptor Fusions Predict Therapeutic Sensitivity. Clin Cancer Res. 2015 Jul 15; 21(14):3105-7. PMID: 25995339.
        View in: PubMed
      32. Hitomi M, Deleyrolle LP, Mulkearns-Hubert EE, Jarrar A, Li M, Sinyuk M, Otvos B, Brunet S, Flavahan WA, Hubert CG, Goan W, Hale JS, Alvarado AG, Zhang A, Rohaus M, Oli M, Vedam-Mai V, Fortin JM, Futch HS, Griffith B, Wu Q, Xia CH, Gong X, Ahluwalia MS, Rich J, Reynolds BA, Lathia JD. Differential connexin function enhances self-renewal in glioblastoma. Cell Rep. 2015 May 19; 11(7):1031-42. PMID: 25959821; PMCID: PMC4502443.
      33. Mathew LK, Huangyang P, Mucaj V, Lee SS, Skuli N, Eisinger-Mathason TS, Biju K, Li B, Venneti S, Lal P, Lathia JD, Rich J, Keith B, Simon MC. Feedback circuitry between miR-218 repression and RTK activation in glioblastoma. Sci Signal. 2015 May 05; 8(375):ra42. PMID: 25943352; PMCID: PMC4437515.
      34. Rivera M, Wu Q, Hamerlik P, Hjelmeland AB, Bao S, Rich J. Acquisition of meiotic DNA repair regulators maintain genome stability in glioblastoma. Cell Death Dis. 2015 Apr 23; 6:e1732. PMID: 25906155; PMCID: PMC4650544.
      35. Xie Q, Wu Q, Horbinski CM, Flavahan WA, Yang K, Zhou W, Dombrowski SM, Huang Z, Fang X, Shi Y, Ferguson AN, Kashatus DF, Bao S, Rich J. Mitochondrial control by DRP1 in brain tumor initiating cells. Nat Neurosci. 2015 Apr; 18(4):501-10. PMID: 25730670; PMCID: PMC4376639.
      36. Man J, Shoemake JD, Ma T, Rizzo AE, Godley AR, Wu Q, Mohammadi AM, Bao S, Rich J, Yu JS. Hyperthermia Sensitizes Glioma Stem-like Cells to Radiation by Inhibiting AKT Signaling. Cancer Res. 2015 Apr 15; 75(8):1760-9. PMID: 25712125; PMCID: PMC4401644.
      37. Phillips C, Brookes CD, Rich J, Arbon J, Turvey TA. Postoperative nausea and vomiting following orthognathic surgery. Int J Oral Maxillofac Surg. 2015 Jun; 44(6):745-51. PMID: 25655765; PMCID: PMC4430405.
      38. Adorno-Cruz V, Kibria G, Liu X, Doherty M, Junk DJ, Guan D, Hubert C, Venere M, Mulkearns-Hubert E, Sinyuk M, Alvarado A, Caplan AI, Rich J, Gerson SL, Lathia J, Liu H. Cancer stem cells: targeting the roots of cancer, seeds of metastasis, and sources of therapy resistance. Cancer Res. 2015 Mar 15; 75(6):924-9. PMID: 25604264; PMCID: PMC4359955.
      39. Zhou W, Ke SQ, Huang Z, Flavahan W, Fang X, Paul J, Wu L, Sloan AE, McLendon RE, Li X, Rich J, Bao S. Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth. Nat Cell Biol. 2015 Feb; 17(2):170-82. PMID: 25580734; PMCID: PMC4312504.
      40. Miller TE, Wang J, Sukhdeo K, Horbinski C, Tesar PJ, Wechsler-Reya RJ, Rich J. Lgr5 Marks Post-Mitotic, Lineage Restricted Cerebellar Granule Neurons during Postnatal Development. PLoS One. 2014; 9(12):e114433. PMID: 25493560.
        View in: PubMed
      41. Grace SM, Rich J, Chin W, Rodriguez HP. Fidelity of implementation to a care team redesign and improved outcomes of diabetes care. Int J Qual Health Care. 2015 Feb; 27(1):60-6. PMID: 25431469.
        View in: PubMed
      42. Stoltz K, Sinyuk M, Hale JS, Wu Q, Otvos B, Walker K, Vasanji A, Rich J, Hjelmeland AB, Lathia JD. Development of a Sox2 reporter system modeling cellular heterogeneity in glioma. Neuro Oncol. 2015 Mar; 17(3):361-71. PMID: 25416826; PMCID: PMC4483103.
      43. Man J, Shoemake J, Zhou W, Fang X, Wu Q, Rizzo A, Prayson R, Bao S, Rich J, Yu JS. Sema3C promotes the survival and tumorigenicity of glioma stem cells through Rac1 activation. Cell Rep. 2014 Dec 11; 9(5):1812-26. PMID: 25464848; PMCID: PMC4268066.
      44. Xie Q, Flavahan WA, Bao S, Rich J. The tailless root of glioma: cancer stem cells. Cell Stem Cell. 2014 Aug 07; 15(2):114-6. PMID: 25105574; PMCID: PMC4239656.
      45. Fang X, Huang Z, Zhou W, Wu Q, Sloan AE, Ouyang G, McLendon RE, Yu JS, Rich J, Bao S. The zinc finger transcription factor ZFX is required for maintaining the tumorigenic potential of glioblastoma stem cells. Stem Cells. 2014 Aug; 32(8):2033-47. PMID: 24831540; PMCID: PMC4349564.
      46. Hale JS, Otvos B, Sinyuk M, Alvarado AG, Hitomi M, Stoltz K, Wu Q, Flavahan W, Levison B, Johansen ML, Schmitt D, Neltner JM, Huang P, Ren B, Sloan AE, Silverstein RL, Gladson CL, DiDonato JA, Brown JM, McIntyre T, Hazen SL, Horbinski C, Rich J, Lathia JD. Cancer stem cell-specific scavenger receptor CD36 drives glioblastoma progression. Stem Cells. 2014 Jul; 32(7):1746-58. PMID: 24737733; PMCID: PMC4063873.
      47. Bai Y, Lathia JD, Zhang P, Flavahan W, Rich J, Mattson MP. Molecular targeting of TRF2 suppresses the growth and tumorigenesis of glioblastoma stem cells. Glia. 2014 Oct; 62(10):1687-98. PMID: 24909307; PMCID: PMC4141001.
      48. Thorne AH, Meisen WH, Russell L, Yoo JY, Bolyard CM, Lathia JD, Rich J, Puduvalli VK, Mao H, Yu J, Caligiuri MA, Tridandapani S, Kaur B. Role of cysteine-rich 61 protein (CCN1) in macrophage-mediated oncolytic herpes simplex virus clearance. Mol Ther. 2014 Sep; 22(9):1678-87. PMID: 24895995.
        View in: PubMed
      49. Ferrarese R, Harsh GR, Yadav AK, Bug E, Maticzka D, Reichardt W, Dombrowski SM, Miller TE, Masilamani AP, Dai F, Kim H, Hadler M, Scholtens DM, Yu IL, Beck J, Srinivasasainagendra V, Costa F, Baxan N, Pfeifer D, von Elverfeldt D, Backofen R, Weyerbrock A, Duarte CW, He X, Prinz M, Chandler JP, Vogel H, Chakravarti A, Rich J, Carro MS, Bredel M. Lineage-specific splicing of a brain-enriched alternative exon promotes glioblastoma progression. J Clin Invest. 2014 Jul; 124(7):2861-76. PMID: 24865424; PMCID: PMC4071411.
      50. Liu JK, Lubelski D, Schonberg DL, Wu Q, Hale JS, Flavahan WA, Mulkearns-Hubert EE, Man J, Hjelmeland AB, Yu J, Lathia JD, Rich J. Phage display discovery of novel molecular targets in glioblastoma-initiating cells. Cell Death Differ. 2014 Aug; 21(8):1325-39. PMID: 24832468; PMCID: PMC4085538.
      51. Rich J, Golden BA, Phillips C. Systematic review of preoperative mandibular canal position as it relates to postoperative neurosensory disturbance following the sagittal split ramus osteotomy. Int J Oral Maxillofac Surg. 2014 Sep; 43(9):1076-81. PMID: 24837554; PMCID: PMC4130761.
      52. Yan K, Wu Q, Yan DH, Lee CH, Rahim N, Tritschler I, DeVecchio J, Kalady MF, Hjelmeland AB, Rich J. Glioma cancer stem cells secrete Gremlin1 to promote their maintenance within the tumor hierarchy. Genes Dev. 2014 May 15; 28(10):1085-100. PMID: 24788093; PMCID: PMC4035537.
      53. Fan Y, Potdar AA, Gong Y, Eswarappa SM, Donnola S, Lathia JD, Hambardzumyan D, Rich J, Fox PL. Profilin-1 phosphorylation directs angiocrine expression and glioblastoma progression through HIF-1a accumulation. Nat Cell Biol. 2014 May; 16(5):445-56. PMID: 24747440; PMCID: PMC4036069.
      54. Miao H, Gale NW, Guo H, Qian J, Petty A, Kaspar J, Murphy AJ, Valenzuela DM, Yancopoulos G, Hambardzumyan D, Lathia JD, Rich J, Lee J, Wang B. EphA2 promotes infiltrative invasion of glioma stem cells in vivo through cross-talk with Akt and regulates stem cell properties. Oncogene. 2015 Jan 29; 34(5):558-67. PMID: 24488013; PMCID: PMC4119862.
      55. Camp CH, Lee YJ, Heddleston JM, Hartshorn CM, Hight Walker AR, Rich J, Lathia JD, Cicerone MT. High-Speed Coherent Raman Fingerprint Imaging of Biological Tissues. Nat Photonics. 2014; 8:627-634. PMID: 25621002.
        View in: PubMed
      56. Lathia JD, Li M, Sinyuk M, Alvarado AG, Flavahan WA, Stoltz K, Rosager AM, Hale J, Hitomi M, Gallagher J, Wu Q, Martin J, Vidal JG, Nakano I, Dahlrot RH, Hansen S, McLendon RE, Sloan AE, Bao S, Hjelmeland AB, Carson CT, Naik UP, Kristensen B, Rich J. High-throughput flow cytometry screening reveals a role for junctional adhesion molecule a as a cancer stem cell maintenance factor. Cell Rep. 2014 Jan 16; 6(1):117-29. PMID: 24373972; PMCID: PMC3899718.
      57. Mathew LK, Skuli N, Mucaj V, Lee SS, Zinn PO, Sathyan P, Imtiyaz HZ, Zhang Z, Davuluri RV, Rao S, Venneti S, Lal P, Lathia JD, Rich J, Keith B, Minn AJ, Simon MC. miR-218 opposes a critical RTK-HIF pathway in mesenchymal glioblastoma. Proc Natl Acad Sci U S A. 2014 Jan 07; 111(1):291-6. PMID: 24368849; PMCID: PMC3890843.
      58. Lotti F, Jarrar AM, Pai RK, Hitomi M, Lathia J, Mace A, Gantt GA, Sukhdeo K, DeVecchio J, Vasanji A, Leahy P, Hjelmeland AB, Kalady MF, Rich J. Chemotherapy activates cancer-associated fibroblasts to maintain colorectal cancer-initiating cells by IL-17A. J Exp Med. 2013 Dec 16; 210(13):2851-72. PMID: 24323355; PMCID: PMC3865474.
      59. Yan K, Yang K, Rich J. The evolving landscape of glioblastoma stem cells. Curr Opin Neurol. 2013 Dec; 26(6):701-7. PMID: 24152818; PMCID: PMC4031658.
      60. Sukhdeo K, Koch CE, Miller TE, Zhou H, Rivera M, Yan K, Cepko CL, Lathia JD, Rich J. The Lgr5 transgene is expressed specifically in glycinergic amacrine cells in the mouse retina. Exp Eye Res. 2014 Feb; 119:106-10. PMID: 24246263; PMCID: PMC3986349.
      61. Zheng Q, Banaszak L, Fracci S, Basali D, Dunlap SM, Hursting SD, Rich J, Hjlemeland AB, Vasanji A, Berger NA, Lathia JD, Reizes O. Leptin receptor maintains cancer stem-like properties in triple negative breast cancer cells. Endocr Relat Cancer. 2013 Dec; 20(6):797-808. PMID: 24025407; PMCID: PMC3843956.
      62. Venere M, Hamerlik P, Wu Q, Rasmussen RD, Song LA, Vasanji A, Tenley N, Flavahan WA, Hjelmeland AB, Bartek J, Rich J. Therapeutic targeting of constitutive PARP activation compromises stem cell phenotype and survival of glioblastoma-initiating cells. Cell Death Differ. 2014 Feb; 21(2):258-69. PMID: 24121277; PMCID: PMC3890948.
      63. Schonberg DL, Bao S, Rich J. Genomics informs glioblastoma biology. Nat Genet. 2013 Oct; 45(10):1105-7. PMID: 24071842.
        View in: PubMed
      64. Flavahan WA, Wu Q, Hitomi M, Rahim N, Kim Y, Sloan AE, Weil RJ, Nakano I, Sarkaria JN, Stringer BW, Day BW, Li M, Lathia JD, Rich J, Hjelmeland AB. Brain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake. Nat Neurosci. 2013 Oct; 16(10):1373-82. PMID: 23995067; PMCID: PMC3930177.
      65. Schonberg DL, Venere M, Rich J. Changing the fate of cancer, one splice at a time. Proc Natl Acad Sci U S A. 2013 Sep 03; 110(36):14510-1. PMID: 23969832; PMCID: PMC3767506.
      66. Cao Y, Eble JM, Moon E, Yuan H, Weitzel DH, Landon CD, Nien CY, Hanna G, Rich J, Provenzale JM, Dewhirst MW. Tumor cells upregulate normoxic HIF-1a in response to doxorubicin. Cancer Res. 2013 Oct 15; 73(20):6230-42. PMID: 23959856; PMCID: PMC3800255.
      67. Schulte JD, Srikanth M, Das S, Zhang J, Lathia JD, Yin L, Rich J, Olson EC, Kessler JA, Chenn A. Cadherin-11 regulates motility in normal cortical neural precursors and glioblastoma. PLoS One. 2013; 8(8):e70962. PMID: 23951053; PMCID: PMC3737231.
      68. Liu WM, Huang P, Kar N, Burgett M, Muller-Greven G, Nowacki AS, Distelhorst CW, Lathia JD, Rich J, Kappes JC, Gladson CL. Lyn facilitates glioblastoma cell survival under conditions of nutrient deprivation by promoting autophagy. PLoS One. 2013; 8(8):e70804. PMID: 23936469; PMCID: PMC3732228.
      69. Schonberg DL, Lubelski D, Miller TE, Rich J. Brain tumor stem cells: Molecular characteristics and their impact on therapy. Mol Aspects Med. 2014 Oct; 39:82-101. PMID: 23831316; PMCID: PMC3866208.
      70. Hale JS, Sinyuk M, Rich J, Lathia JD. Decoding the cancer stem cell hypothesis in glioblastoma. CNS Oncol. 2013 Jul; 2(4):319-30. PMID: 24379973; PMCID: PMC3873749.
      71. Kim Y, Wu Q, Hamerlik P, Hitomi M, Sloan AE, Barnett GH, Weil RJ, Leahy P, Hjelmeland AB, Rich J. Aptamer identification of brain tumor-initiating cells. Cancer Res. 2013 Aug 01; 73(15):4923-36. PMID: 23796560; PMCID: PMC3933790.
      72. Kim E, Kim M, Woo DH, Shin Y, Shin J, Chang N, Oh YT, Kim H, Rheey J, Nakano I, Lee C, Joo KM, Rich J, Nam DH, Lee J. Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell. 2013 Jun 10; 23(6):839-52. PMID: 23684459; PMCID: PMC4109796.
      73. Wang H, Han M, Whetsell W, Wang J, Rich J, Hallahan D, Han Z. Tax-interacting protein 1 coordinates the spatiotemporal activation of Rho GTPases and regulates the infiltrative growth of human glioblastoma. Oncogene. 2014 Mar 20; 33(12):1558-69. PMID: 23563176; PMCID: PMC3965267.
      74. Xu C, Xie D, Yu SC, Yang XJ, He LR, Yang J, Ping YF, Wang B, Yang L, Xu SL, Cui W, Wang QL, Fu WJ, Liu Q, Qian C, Cui YH, Rich J, Kung HF, Zhang X, Bian XW. ß-Catenin/POU5F1/SOX2 transcription factor complex mediates IGF-I receptor signaling and predicts poor prognosis in lung adenocarcinoma. Cancer Res. 2013 May 15; 73(10):3181-9. PMID: 23539445.
        View in: PubMed
      75. Cheng L, Huang Z, Zhou W, Wu Q, Donnola S, Liu JK, Fang X, Sloan AE, Mao Y, Lathia JD, Min W, McLendon RE, Rich J, Bao S. Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell. 2013 Mar 28; 153(1):139-52. PMID: 23540695; PMCID: PMC3638263.
      76. Venere M, Lathia JD, Rich J. Growth factor receptors define cancer hierarchies. Cancer Cell. 2013 Feb 11; 23(2):135-7. PMID: 23410969; PMCID: PMC3616317.
      77. Venere M, Miller TE, Rich J. Mitotic control of cancer stem cells. Cancer Discov. 2013 Feb; 3(2):141-4. PMID: 23400473; PMCID: PMC3616319.
      78. Sukhdeo K, Paramban RI, Vidal JG, Elia J, Martin J, Rivera M, Carrasco DR, Jarrar A, Kalady MF, Carson CT, Balderas R, Hjelmeland AB, Lathia JD, Rich J. Multiplex flow cytometry barcoding and antibody arrays identify surface antigen profiles of primary and metastatic colon cancer cell lines. PLoS One. 2013; 8(1):e53015. PMID: 23308131; PMCID: PMC3538639.
      79. Lathia JD, Li M, Hall PE, Gallagher J, Hale JS, Wu Q, Venere M, Levy E, Rani MR, Huang P, Bae E, Selfridge J, Cheng L, Guvenc H, McLendon RE, Nakano I, Sloan AE, Phillips HS, Lai A, Gladson CL, Bredel M, Bao S, Hjelmeland AB, Rich J. Laminin alpha 2 enables glioblastoma stem cell growth. Ann Neurol. 2012 Nov; 72(5):766-78. PMID: 23280793; PMCID: PMC3615417.
      80. Reardon DA, Herndon JE, Peters KB, Desjardins A, Coan A, Lou E, Sumrall AL, Turner S, Lipp ES, Sathornsumetee S, Rich J, Sampson JH, Friedman AH, Boulton ST, Bigner DD, Friedman HS, Vredenburgh JJ. Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients. Br J Cancer. 2012 Oct 23; 107(9):1481-7. PMID: 23037712; PMCID: PMC3493761.
      81. Eyler CE, Rich J. Looking in the miR-ror: TGF-ß-mediated activation of NF-?B in glioma. J Clin Invest. 2012 Oct; 122(10):3473-5. PMID: 23006324; PMCID: PMC3461933.
      82. Schonberg DL, Bao S, Rich J. TRP-ing up brain tumors. Nat Med. 2012 Aug; 18(8):1175-6. PMID: 22869181.
        View in: PubMed
      83. Li M, Hale JS, Rich J, Ransohoff RM, Lathia JD. Chemokine CXCL12 in neurodegenerative diseases: an SOS signal for stem cell-based repair. Trends Neurosci. 2012 Oct; 35(10):619-28. PMID: 22784557; PMCID: PMC3461091.
      84. Hjelmeland AB, Rich J. The quest for self-identity: not all cancer stem cells are the same. Clin Cancer Res. 2012 Jul 01; 18(13):3495-8. PMID: 22711710; PMCID: PMC3389128.
      85. Rich J, Raviv A, Raviv N, Brietzke SE. All-cause mortality and obstructive sleep apnea severity revisited. Otolaryngol Head Neck Surg. 2012 Sep; 147(3):583-7. PMID: 22687326.
        View in: PubMed
      86. Kim Y, Kim E, Wu Q, Guryanova O, Hitomi M, Lathia JD, Serwanski D, Sloan AE, Weil RJ, Lee J, Nishiyama A, Bao S, Hjelmeland AB, Rich J. Platelet-derived growth factor receptors differentially inform intertumoral and intratumoral heterogeneity. Genes Dev. 2012 Jun 01; 26(11):1247-62. PMID: 22661233; PMCID: PMC3371412.
      87. Joo KM, Jin J, Kim E, Ho Kim K, Kim Y, Gu Kang B, Kang YJ, Lathia JD, Cheong KH, Song PH, Kim H, Seol HJ, Kong DS, Lee JI, Rich J, Lee J, Nam DH. MET signaling regulates glioblastoma stem cells. Cancer Res. 2012 Aug 01; 72(15):3828-38. PMID: 22617325.
        View in: PubMed
      88. Lathia JD, Rich J. Holding on to stemness. Nat Cell Biol. 2012 May 02; 14(5):450-2. PMID: 22552145.
        View in: PubMed
      89. Reardon DA, Vredenburgh JJ, Desjardins A, Peters KB, Sathornsumetee S, Threatt S, Sampson JH, Herndon JE, Coan A, McSherry F, Rich J, McLendon RE, Zhang S, Friedman HS. Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma. J Neurooncol. 2012 Jul; 108(3):499-506. PMID: 22407177; PMCID: PMC3690584.
      90. Huang P, Rani MR, Ahluwalia MS, Bae E, Prayson RA, Weil RJ, Nowacki AS, Hedayat H, Sloan AE, Lathia JD, Rich J, Tipps R, Gladson CL. Endothelial expression of TNF receptor-1 generates a proapoptotic signal inhibited by integrin a6ß1 in glioblastoma. Cancer Res. 2012 Mar 15; 72(6):1428-37. PMID: 22396498; PMCID: PMC3428239.
      91. Hamerlik P, Lathia JD, Rasmussen R, Wu Q, Bartkova J, Lee M, Moudry P, Bartek J, Fischer W, Lukas J, Rich J, Bartek J. Autocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth. J Exp Med. 2012 Mar 12; 209(3):507-20. PMID: 22393126; PMCID: PMC3302235.
      92. Reardon DA, Desjardins A, Vredenburgh JJ, Herndon JE, Coan A, Gururangan S, Peters KB, McLendon R, Sathornsumetee S, Rich J, Lipp ES, Janney D, Friedman HS. Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma. Cancer. 2012 Oct 01; 118(19):4759-67. PMID: 22371319; PMCID: PMC3748946.
      93. Wang J, Sullenger BA, Rich J. Notch signaling in cancer stem cells. Adv Exp Med Biol. 2012; 727:174-85. PMID: 22399347.
        View in: PubMed
      94. Sathornsumetee S, Rich J. Molecularly targeted therapy in neuro-oncology. Handb Clin Neurol. 2012; 104:255-78. PMID: 22230448.
        View in: PubMed
      95. Chin BB, Hjelemand A, Rich J, Song H, Lascola C, Storms R, McLendon R, Reiman R, Greer KL, Metzler SD, McDougald D, Dai D, Vaidyanathan G. Synthesis and preliminary evaluation of n.c.a. iodoquine: a novel radiotracer with high uptake in cells with high ALDH1 expression. Curr Radiopharm. 2012 Jan; 5(1):47-58. PMID: 21864242.
        View in: PubMed
      96. Hjelmeland AB, Lathia JD, Sathornsumetee S, Rich J. Twisted tango: brain tumor neurovascular interactions. Nat Neurosci. 2011 Oct 26; 14(11):1375-81. PMID: 22030548; PMCID: PMC3615423.
      97. Reardon DA, Herndon JE, Peters K, Desjardins A, Coan A, Lou E, Sumrall A, Turner S, Sathornsumetee S, Rich J, Boulton S, Lipp ES, Friedman HS, Vredenburgh JJ. Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients. J Neurooncol. 2012 Mar; 107(1):213-21. PMID: 21997879; PMCID: PMC3403724.
      98. Reardon DA, Cloughesy T, Rich J, Alfred Yung WK, Yung L, DiLea C, Huang J, Dugan M, Mietlowski W, Maes A, Conrad C. Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma. Cancer Chemother Pharmacol. 2012 Jan; 69(1):281-7. PMID: 21984222.
        View in: PubMed
      99. Lathia JD, Gallagher J, Myers JT, Li M, Vasanji A, McLendon RE, Hjelmeland AB, Huang AY, Rich J. Direct in vivo evidence for tumor propagation by glioblastoma cancer stem cells. PLoS One. 2011; 6(9):e24807. PMID: 21961046; PMCID: PMC3178553.
      100. Lathia JD, Hitomi M, Gallagher J, Gadani SP, Adkins J, Vasanji A, Liu L, Eyler CE, Heddleston JM, Wu Q, Minhas S, Soeda A, Hoeppner DJ, Ravin R, McKay RD, McLendon RE, Corbeil D, Chenn A, Hjelmeland AB, Park DM, Rich J. Distribution of CD133 reveals glioma stem cells self-renew through symmetric and asymmetric cell divisions. Cell Death Dis. 2011 Sep 01; 2:e200. PMID: 21881602; PMCID: PMC3186899.
      101. Hanses F, Park S, Rich J, Lee JC. Reduced neutrophil apoptosis in diabetic mice during staphylococcal infection leads to prolonged Tnfa production and reduced neutrophil clearance. PLoS One. 2011; 6(8):e23633. PMID: 21912601; PMCID: PMC3166063.
      102. Heddleston JM, Wu Q, Rivera M, Minhas S, Lathia JD, Sloan AE, Iliopoulos O, Hjelmeland AB, Rich J. Hypoxia-induced mixed-lineage leukemia 1 regulates glioma stem cell tumorigenic potential. Cell Death Differ. 2012 Mar; 19(3):428-39. PMID: 21836617; PMCID: PMC3229666.
      103. Rich J, Raviv A, Raviv N, Brietzke SE. An epidemiologic study of snoring and all-cause mortality. Otolaryngol Head Neck Surg. 2011 Aug; 145(2):341-6. PMID: 21493281.
        View in: PubMed
      104. Sukhdeo K, Hambardzumyan D, Rich J. Glioma development: where did it all go wrong? Cell. 2011 Jul 22; 146(2):187-8. PMID: 21784240.
        View in: PubMed
      105. Zheng Q, Dunlap SM, Zhu J, Downs-Kelly E, Rich J, Hursting SD, Berger NA, Reizes O. Leptin deficiency suppresses MMTV-Wnt-1 mammary tumor growth in obese mice and abrogates tumor initiating cell survival. Endocr Relat Cancer. 2011 Aug; 18(4):491-503. PMID: 21636700; PMCID: PMC3197719.
      106. Reardon DA, Vredenburgh JJ, Coan A, Desjardins A, Peters KB, Gururangan S, Sathornsumetee S, Rich J, Herndon JE, Friedman HS. Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma. J Neurooncol. 2011 Dec; 105(3):621-7. PMID: 21744079; PMCID: PMC3748953.
      107. Eyler CE, Wu Q, Yan K, MacSwords JM, Chandler-Militello D, Misuraca KL, Lathia JD, Forrester MT, Lee J, Stamler JS, Goldman SA, Bredel M, McLendon RE, Sloan AE, Hjelmeland AB, Rich J. Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2. Cell. 2011 Jul 08; 146(1):53-66. PMID: 21729780; PMCID: PMC3144745.
      108. Mathieu J, Zhang Z, Zhou W, Wang AJ, Heddleston JM, Pinna CM, Hubaud A, Stadler B, Choi M, Bar M, Tewari M, Liu A, Vessella R, Rostomily R, Born D, Horwitz M, Ware C, Blau CA, Cleary MA, Rich J, Ruohola-Baker H. HIF induces human embryonic stem cell markers in cancer cells. Cancer Res. 2011 Jul 01; 71(13):4640-52. PMID: 21712410; PMCID: PMC3129496.
      109. Lathia JD, Venere M, Rao MS, Rich J. Seeing is believing: are cancer stem cells the Loch Ness monster of tumor biology? Stem Cell Rev. 2011 Jun; 7(2):227-37. PMID: 20957452; PMCID: PMC3093710.
      110. Lathia JD, Heddleston JM, Venere M, Rich J. Deadly teamwork: neural cancer stem cells and the tumor microenvironment. Cell Stem Cell. 2011 May 06; 8(5):482-5. PMID: 21549324; PMCID: PMC3494093.
      111. Venere M, Fine HA, Dirks PB, Rich J. Cancer stem cells in gliomas: identifying and understanding the apex cell in cancer's hierarchy. Glia. 2011 Aug; 59(8):1148-54. PMID: 21547954; PMCID: PMC3107874.
      112. Guryanova OA, Wu Q, Cheng L, Lathia JD, Huang Z, Yang J, MacSwords J, Eyler CE, McLendon RE, Heddleston JM, Shou W, Hambardzumyan D, Lee J, Hjelmeland AB, Sloan AE, Bredel M, Stark GR, Rich J, Bao S. Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3. Cancer Cell. 2011 Apr 12; 19(4):498-511. PMID: 21481791; PMCID: PMC3076106.
      113. Cheng L, Wu Q, Guryanova OA, Huang Z, Huang Q, Rich J, Bao S. Elevated invasive potential of glioblastoma stem cells. Biochem Biophys Res Commun. 2011 Mar 25; 406(4):643-8. PMID: 21371437; PMCID: PMC3065536.
      114. Cheng L, Wu Q, Huang Z, Guryanova OA, Huang Q, Shou W, Rich J, Bao S. L1CAM regulates DNA damage checkpoint response of glioblastoma stem cells through NBS1. EMBO J. 2011 Mar 02; 30(5):800-13. PMID: 21297581; PMCID: PMC3049209.
      115. Huang Z, Wu Q, Guryanova OA, Cheng L, Shou W, Rich J, Bao S. Deubiquitylase HAUSP stabilizes REST and promotes maintenance of neural progenitor cells. Nat Cell Biol. 2011 Feb; 13(2):142-52. PMID: 21258371; PMCID: PMC3076066.
      116. Hjelmeland AB, Rich J. Molecular targeting of neural cancer stem cells: TTAGGG, you're it! Clin Cancer Res. 2011 Jan 01; 17(1):3-5. PMID: 21208901; PMCID: PMC3099413.
      117. Forrester MT, Eyler CE, Rich J. Bacterial flavohemoglobin: a molecular tool to probe mammalian nitric oxide biology. Biotechniques. 2011 Jan; 50(1):41-5. PMID: 21231921; PMCID: PMC3096140.
      118. Heddleston JM, Hitomi M, Venere M, Flavahan WA, Yang K, Kim Y, Minhas S, Rich J, Hjelmeland AB. Glioma stem cell maintenance: the role of the microenvironment. Curr Pharm Des. 2011; 17(23):2386-401. PMID: 21827414; PMCID: PMC3615428.
      119. Shats I, Gatza ML, Chang JT, Mori S, Wang J, Rich J, Nevins JR. Using a stem cell-based signature to guide therapeutic selection in cancer. Cancer Res. 2011 Mar 01; 71(5):1772-80. PMID: 21169407; PMCID: PMC3049992.
      120. Hjelmeland AB, Wu Q, Heddleston JM, Choudhary GS, MacSwords J, Lathia JD, McLendon R, Lindner D, Sloan A, Rich J. Acidic stress promotes a glioma stem cell phenotype. Cell Death Differ. 2011 May; 18(5):829-40. PMID: 21127501; PMCID: PMC3095828.
      121. McLendon RE, Rich J. Glioblastoma Stem Cells: A Neuropathologist's View. J Oncol. 2011; 2011:397195. PMID: 21052560; PMCID: PMC2971570.
      122. Sheehan JP, Shaffrey ME, Gupta B, Larner J, Rich J, Park DM. Improving the radiosensitivity of radioresistant and hypoxic glioblastoma. Future Oncol. 2010 Oct; 6(10):1591-601. PMID: 21062158.
        View in: PubMed
      123. Reardon DA, Desjardins A, Peters K, Gururangan S, Sampson J, Rich J, McLendon R, Herndon JE, Marcello J, Threatt S, Friedman AH, Vredenburgh JJ, Friedman HS. Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. J Neurooncol. 2011 Jun; 103(2):371-9. PMID: 20853132; PMCID: PMC3102515.
      124. Sathornsumetee S, Desjardins A, Vredenburgh JJ, McLendon RE, Marcello J, Herndon JE, Mathe A, Hamilton M, Rich J, Norfleet JA, Gururangan S, Friedman HS, Reardon DA. Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro Oncol. 2010 Dec; 12(12):1300-10. PMID: 20716591; PMCID: PMC3018944.
      125. Weinberg R, Fisher DE, Rich J. Dynamic and transient cancer stem cells nurture melanoma. Nat Med. 2010 Jul; 16(7):758. PMID: 20613753.
        View in: PubMed
      126. Cheng L, Bao S, Rich J. Potential therapeutic implications of cancer stem cells in glioblastoma. Biochem Pharmacol. 2010 Sep 01; 80(5):654-65. PMID: 20457135; PMCID: PMC2897968.
      127. Lathia JD, Gallagher J, Heddleston JM, Wang J, Eyler CE, Macswords J, Wu Q, Vasanji A, McLendon RE, Hjelmeland AB, Rich J. Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem Cell. 2010 May 07; 6(5):421-32. PMID: 20452317; PMCID: PMC2884275.
      128. Nadeau DP, Rich J, Brietzke SE. Informed consent in pediatric surgery: Do parents understand the risks? Arch Otolaryngol Head Neck Surg. 2010 Mar; 136(3):265-9. PMID: 20231645.
        View in: PubMed
      129. Hjelmeland AB, Wu Q, Wickman S, Eyler C, Heddleston J, Shi Q, Lathia JD, Macswords J, Lee J, McLendon RE, Rich J. Targeting A20 decreases glioma stem cell survival and tumor growth. PLoS Biol. 2010 Feb 23; 8(2):e1000319. PMID: 20186265; PMCID: PMC2826371.
      130. Park DM, Sathornsumetee S, Rich J. Medical oncology: treatment and management of malignant gliomas. Nat Rev Clin Oncol. 2010 Feb; 7(2):75-7. PMID: 20118976.
        View in: PubMed
      131. Heddleston JM, Li Z, Lathia JD, Bao S, Hjelmeland AB, Rich J. Hypoxia inducible factors in cancer stem cells. Br J Cancer. 2010 Mar 02; 102(5):789-95. PMID: 20104230; PMCID: PMC2833246.
      132. Cao Y, Lathia JD, Eyler CE, Wu Q, Li Z, Wang H, McLendon RE, Hjelmeland AB, Rich J. Erythropoietin Receptor Signaling Through STAT3 Is Required For Glioma Stem Cell Maintenance. Genes Cancer. 2010 Jan 01; 1(1):50-61. PMID: 20657792.
        View in: PubMed
      133. Li Z, Rich J. Hypoxia and hypoxia inducible factors in cancer stem cell maintenance. Curr Top Microbiol Immunol. 2010; 345:21-30. PMID: 20582533.
        View in: PubMed
      134. Wang J, Wakeman TP, Lathia JD, Hjelmeland AB, Wang XF, White RR, Rich J, Sullenger BA. Notch promotes radioresistance of glioma stem cells. Stem Cells. 2010 Jan; 28(1):17-28. PMID: 19921751; PMCID: PMC2825687.
      135. Chigurupati S, Venkataraman R, Barrera D, Naganathan A, Madan M, Paul L, Pattisapu JV, Kyriazis GA, Sugaya K, Bushnev S, Lathia JD, Rich J, Chan SL. Receptor channel TRPC6 is a key mediator of Notch-driven glioblastoma growth and invasiveness. Cancer Res. 2010 Jan 01; 70(1):418-27. PMID: 20028870.
        View in: PubMed
      136. Heddleston JM, Li Z, McLendon RE, Hjelmeland AB, Rich J. The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle. 2009 Oct 15; 8(20):3274-84. PMID: 19770585; PMCID: PMC2825672.
      137. Wang H, Lathia JD, Wu Q, Wang J, Li Z, Heddleston JM, Eyler CE, Elderbroom J, Gallagher J, Schuschu J, MacSwords J, Cao Y, McLendon RE, Wang XF, Hjelmeland AB, Rich J. Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth. Stem Cells. 2009 Oct; 27(10):2393-404. PMID: 19658188; PMCID: PMC2825688.
      138. Zhang P, Lathia JD, Flavahan WA, Rich J, Mattson MP. Squelching glioblastoma stem cells by targeting REST for proteasomal degradation. Trends Neurosci. 2009 Nov; 32(11):559-65. PMID: 19748686; PMCID: PMC2767465.
      139. Affronti ML, Heery CR, Herndon JE, Rich J, Reardon DA, Desjardins A, Vredenburgh JJ, Friedman AH, Bigner DD, Friedman HS. Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy. Cancer. 2009 Aug 01; 115(15):3501-11. PMID: 19514083.
        View in: PubMed
      140. Park DM, Rich J. Biology of glioma cancer stem cells. Mol Cells. 2009 Jul 31; 28(1):7-12. PMID: 19655094.
        View in: PubMed
      141. Schilling SH, Hjelmeland AB, Radiloff DR, Liu IM, Wakeman TP, Fielhauer JR, Foster EH, Lathia JD, Rich J, Wang XF, Datto MB. NDRG4 is required for cell cycle progression and survival in glioblastoma cells. J Biol Chem. 2009 Sep 11; 284(37):25160-9. PMID: 19592488; PMCID: PMC2757219.
      142. Li Z, Bao S, Wu Q, Wang H, Eyler C, Sathornsumetee S, Shi Q, Cao Y, Lathia J, McLendon RE, Hjelmeland AB, Rich J. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell. 2009 Jun 02; 15(6):501-13. PMID: 19477429; PMCID: PMC2693960.
      143. Rich J, Eyler CE. Cancer stem cells in brain tumor biology. Cold Spring Harb Symp Quant Biol. 2008; 73:411-20. PMID: 19329578; PMCID: PMC2822444.
      144. Quinn JA, Jiang SX, Reardon DA, Desjardins A, Vredenburgh JJ, Rich J, Gururangan S, Friedman AH, Bigner DD, Sampson JH, McLendon RE, Herndon JE, Walker A, Friedman HS. Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma. Neuro Oncol. 2009 Oct; 11(5):556-61. PMID: 19289491; PMCID: PMC2765345.
      145. Li Z, Wang H, Eyler CE, Hjelmeland AB, Rich J. Turning cancer stem cells inside out: an exploration of glioma stem cell signaling pathways. J Biol Chem. 2009 Jun 19; 284(25):16705-9. PMID: 19286664; PMCID: PMC2719304.
      146. Quinn JA, Jiang SX, Reardon DA, Desjardins A, Vredenburgh JJ, Rich J, Gururangan S, Friedman AH, Bigner DD, Sampson JH, McLendon RE, Herndon JE, Walker A, Friedman HS. Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J Clin Oncol. 2009 Mar 10; 27(8):1262-7. PMID: 19204199; PMCID: PMC2667825.
      147. Quinn JA, Jiang SX, Carter J, Reardon DA, Desjardins A, Vredenburgh JJ, Rich J, Gururangan S, Friedman AH, Bigner DD, Sampson JH, McLendon RE, Herndon JE, Threatt S, Friedman HS. Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme. Clin Cancer Res. 2009 Feb 01; 15(3):1064-8. PMID: 19188181; PMCID: PMC2710963.
      148. Park S, Rich J, Hanses F, Lee JC. Defects in innate immunity predispose C57BL/6J-Leprdb/Leprdb mice to infection by Staphylococcus aureus. Infect Immun. 2009 Mar; 77(3):1008-14. PMID: 19103772; PMCID: PMC2643648.
      149. Wang J, Wang H, Li Z, Wu Q, Lathia JD, McLendon RE, Hjelmeland AB, Rich J. c-Myc is required for maintenance of glioma cancer stem cells. PLoS One. 2008; 3(11):e3769. PMID: 19020659; PMCID: PMC2582454.
      150. Desjardins A, Reardon DA, Herndon JE, Marcello J, Quinn JA, Rich J, Sathornsumetee S, Gururangan S, Sampson J, Bailey L, Bigner DD, Friedman AH, Friedman HS, Vredenburgh JJ. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin Cancer Res. 2008 Nov 01; 14(21):7068-73. PMID: 18981004; PMCID: PMC3671765.
      151. Sathornsumetee S, Rich J. Designer therapies for glioblastoma multiforme. Ann N Y Acad Sci. 2008 Oct; 1142:108-32. PMID: 18990124.
        View in: PubMed
      152. Eyler CE, Foo WC, LaFiura KM, McLendon RE, Hjelmeland AB, Rich J. Brain cancer stem cells display preferential sensitivity to Akt inhibition. Stem Cells. 2008 Dec; 26(12):3027-36. PMID: 18802038; PMCID: PMC2739007.
      153. Gururangan S, Krauser J, Watral MA, Driscoll T, Larrier N, Reardon DA, Rich J, Quinn JA, Vredenburgh JJ, Desjardins A, McLendon RE, Fuchs H, Kurtzberg J, Friedman HS. Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastoma. Neuro Oncol. 2008 Oct; 10(5):745-51. PMID: 18755919; PMCID: PMC2666251.
      154. Bao S, Wu Q, Li Z, Sathornsumetee S, Wang H, McLendon RE, Hjelmeland AB, Rich J. Targeting cancer stem cells through L1CAM suppresses glioma growth. Cancer Res. 2008 Aug 01; 68(15):6043-8. PMID: 18676824; PMCID: PMC2739001.
      155. Eyler CE, Rich J. Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol. 2008 Jun 10; 26(17):2839-45. PMID: 18539962; PMCID: PMC2739000.
      156. Rich J. The Implications of the Cancer Stem Cell Hypothesis for Neuro-Oncology and Neurology. Future Neurol. 2008 May 01; 3(3):265-273. PMID: 19763280.
        View in: PubMed
      157. Reardon DA, Desjardins A, Vredenburgh JJ, Sathornsumetee S, Rich J, Quinn JA, Lagattuta TF, Egorin MJ, Gururangan S, McLendon R, Herndon JE, Friedman AH, Salvado AJ, Friedman HS. Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma. Neuro Oncol. 2008 Jun; 10(3):330-40. PMID: 18359865; PMCID: PMC2563055.
      158. Reardon DA, Zalutsky MR, Akabani G, Coleman RE, Friedman AH, Herndon JE, McLendon RE, Pegram CN, Quinn JA, Rich J, Vredenburgh JJ, Desjardins A, Guruangan S, Boulton S, Raynor RH, Dowell JM, Wong TZ, Zhao XG, Friedman HS, Bigner DD. A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost. Neuro Oncol. 2008 Apr; 10(2):182-9. PMID: 18287339; PMCID: PMC2613820.
      159. Reardon DA, Desjardins A, Rich J, Vredenburgh JJ. The emerging role of anti-angiogenic therapy for malignant glioma. Curr Treat Options Oncol. 2008 Feb; 9(1):1-22. PMID: 18256938.
        View in: PubMed
      160. Sathornsumetee S, Cao Y, Marcello JE, Herndon JE, McLendon RE, Desjardins A, Friedman HS, Dewhirst MW, Vredenburgh JJ, Rich J. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol. 2008 Jan 10; 26(2):271-8. PMID: 18182667; PMCID: PMC3930173.
      161. Sathornsumetee S, Rich J, Reardon DA. Diagnosis and treatment of high-grade astrocytoma. Neurol Clin. 2007 Nov; 25(4):1111-39, x. PMID: 17964028.
        View in: PubMed
      162. Vredenburgh JJ, Desjardins A, Herndon JE, Marcello J, Reardon DA, Quinn JA, Rich J, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007 Oct 20; 25(30):4722-9. PMID: 17947719.
        View in: PubMed
      163. Rich J, Bao S. Chemotherapy and cancer stem cells. Cell Stem Cell. 2007 Oct 11; 1(4):353-5. PMID: 18371369.
        View in: PubMed
      164. Rich J. Cancer stem cells in radiation resistance. Cancer Res. 2007 Oct 01; 67(19):8980-4. PMID: 17908997.
        View in: PubMed
      165. McLendon RE, Turner K, Perkinson K, Rich J. Second messenger systems in human gliomas. Arch Pathol Lab Med. 2007 Oct; 131(10):1585-90. PMID: 17922598.
        View in: PubMed
      166. Gilbertson RJ, Rich J. Making a tumour's bed: glioblastoma stem cells and the vascular niche. Nat Rev Cancer. 2007 10; 7(10):733-6. PMID: 17882276.
        View in: PubMed
      167. Hjelmeland AB, Lattimore KP, Fee BE, Shi Q, Wickman S, Keir ST, Hjelmeland MD, Batt D, Bigner DD, Friedman HS, Rich J. The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasion. Mol Cancer Ther. 2007 Sep; 6(9):2449-57. PMID: 17766837.
        View in: PubMed
      168. Sathornsumetee S, Reardon DA, Desjardins A, Quinn JA, Vredenburgh JJ, Rich J. Molecularly targeted therapy for malignant glioma. Cancer. 2007 Jul 01; 110(1):13-24. PMID: 17520692.
        View in: PubMed
      169. Shi Q, Hjelmeland AB, Keir ST, Song L, Wickman S, Jackson D, Ohmori O, Bigner DD, Friedman HS, Rich J. A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth. Mol Carcinog. 2007 Jun; 46(6):488-96. PMID: 17219439.
        View in: PubMed
      170. Sathornsumetee S, DesJardins A, Reardon DA, Rich J, Vredenburgh JJ. Neurofibromatosis type 2. Neurology. 2007 Mar 27; 68(13):E14. PMID: 17389295.
        View in: PubMed
      171. Vredenburgh JJ, Desjardins A, Herndon JE, Dowell JM, Reardon DA, Quinn JA, Rich J, Sathornsumetee S, Gururangan S, Wagner M, Bigner DD, Friedman AH, Friedman HS. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007 Feb 15; 13(4):1253-9. PMID: 17317837.
        View in: PubMed
      172. Desjardins A, Quinn JA, Vredenburgh JJ, Sathornsumetee S, Friedman AH, Herndon JE, McLendon RE, Provenzale JM, Rich J, Sampson JH, Gururangan S, Dowell JM, Salvado A, Friedman HS, Reardon DA. Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. J Neurooncol. 2007 May; 83(1):53-60. PMID: 17245623.
        View in: PubMed
      173. Shi Q, Bao S, Song L, Wu Q, Bigner DD, Hjelmeland AB, Rich J. Targeting SPARC expression decreases glioma cellular survival and invasion associated with reduced activities of FAK and ILK kinases. Oncogene. 2007 Jun 14; 26(28):4084-94. PMID: 17213807.
        View in: PubMed
      174. Sathornsumetee S, Rich J. Antiangiogenic therapy in malignant glioma: promise and challenge. Curr Pharm Des. 2007; 13(35):3545-58. PMID: 18220791.
        View in: PubMed
      175. Sathornsumetee S, Vredenburgh KA, Lattimore KP, Rich J. Malignant glioma drug discovery - targeting protein kinases. Expert Opin Drug Discov. 2007 Jan; 2(1):1-17. PMID: 23496034.
        View in: PubMed
      176. Badruddoja MA, Penne K, Desjardins A, Reardon DA, Rich J, Quinn JA, Sathornsumetee S, Friedman AH, Bigner DD, Herndon JE, Cahill A, Friedman HS, Vredenburgh JJ. Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme. Neuro Oncol. 2007 Jan; 9(1):70-4. PMID: 17108065; PMCID: PMC1828104.
      177. Rich J. The cancer stem cell: a new therapeutic paradigm? Expert Rev Anticancer Ther. 2006 Nov; 6(11):1531-3. PMID: 17134357.
        View in: PubMed
      178. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich J. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006 Dec 07; 444(7120):756-60. PMID: 17051156.
        View in: PubMed
      179. Sathornsumetee S, Rich J. Vandetanib, a novel multitargeted kinase inhibitor, in cancer therapy. Drugs Today (Barc). 2006 Oct; 42(10):657-70. PMID: 17136225.
        View in: PubMed
      180. Sathornsumetee S, Rich J. New approaches to primary brain tumor treatment. Anticancer Drugs. 2006 Oct; 17(9):1003-16. PMID: 17001172.
        View in: PubMed
      181. DeKroon R, Robinette JB, Hjelmeland AB, Wiggins E, Blackwell M, Mihovilovic M, Fujii M, York J, Hart J, Kontos C, Rich J, Strittmatter WJ. APOE4-VLDL inhibits the HDL-activated phosphatidylinositol 3-kinase/Akt Pathway via the phosphoinositol phosphatase SHIP2. Circ Res. 2006 Oct 13; 99(8):829-36. PMID: 16973905.
        View in: PubMed
      182. Sathornsumetee S, Hjelmeland AB, Keir ST, McLendon RE, Batt D, Ramsey T, Yusuff N, Rasheed BK, Kieran MW, Laforme A, Bigner DD, Friedman HS, Rich J. AAL881, a novel small molecule inhibitor of RAF and vascular endothelial growth factor receptor activities, blocks the growth of malignant glioma. Cancer Res. 2006 Sep 01; 66(17):8722-30. PMID: 16951188.
        View in: PubMed
      183. Bao S, Wu Q, Sathornsumetee S, Hao Y, Li Z, Hjelmeland AB, Shi Q, McLendon RE, Bigner DD, Rich J. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res. 2006 Aug 15; 66(16):7843-8. PMID: 16912155.
        View in: PubMed
      184. Sathornsumetee S, Rich J. New treatment strategies for malignant gliomas. Expert Rev Anticancer Ther. 2006 Jul; 6(7):1087-104. PMID: 16831080.
        View in: PubMed
      185. McLoughlin RM, Solinga RM, Rich J, Zaleski KJ, Cocchiaro JL, Risley A, Tzianabos AO, Lee JC. CD4+ T cells and CXC chemokines modulate the pathogenesis of Staphylococcus aureus wound infections. Proc Natl Acad Sci U S A. 2006 Jul 05; 103(27):10408-13. PMID: 16801559; PMCID: PMC1502471.
      186. Reardon DA, Quinn JA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE, McLendon RE, Pegram CN, Provenzale JM, Dowell JM, Rich J, Vredenburgh JJ, Desjardins A, Sampson JH, Gururangan S, Wong TZ, Badruddoja MA, Zhao XG, Bigner DD, Zalutsky MR. Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results. J Nucl Med. 2006 Jun; 47(6):912-8. PMID: 16741299.
        View in: PubMed
      187. Reardon DA, Rich J, Friedman HS, Bigner DD. Recent advances in the treatment of malignant astrocytoma. J Clin Oncol. 2006 Mar 10; 24(8):1253-65. PMID: 16525180.
        View in: PubMed
      188. Reardon DA, Quinn JA, Vredenburgh JJ, Gururangan S, Friedman AH, Desjardins A, Sathornsumetee S, Herndon JE, Dowell JM, McLendon RE, Provenzale JM, Sampson JH, Smith RP, Swaisland AJ, Ochs JS, Lyons P, Tourt-Uhlig S, Bigner DD, Friedman HS, Rich J. Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clin Cancer Res. 2006 Feb 01; 12(3 Pt 1):860-8. PMID: 16467100.
        View in: PubMed
      189. Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE, McLendon RE, Pegram CN, Provenzale JM, Quinn JA, Rich J, Vredenburgh JJ, Desjardins A, Gururangan S, Guruangan S, Badruddoja M, Dowell JM, Wong TZ, Zhao XG, Zalutsky MR, Bigner DD. Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. J Clin Oncol. 2006 Jan 01; 24(1):115-22. PMID: 16382120.
        View in: PubMed
      190. Reardon DA, Egorin MJ, Quinn JA, Rich JN, Rich JN, Gururangan S, Gururangan I, Vredenburgh JJ, Desjardins A, Sathornsumetee S, Provenzale JM, Herndon JE, Dowell JM, Badruddoja MA, McLendon RE, Lagattuta TF, Kicielinski KP, Dresemann G, Sampson JH, Friedman AH, Salvado AJ, Friedman HS. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol. 2005 Dec 20; 23(36):9359-68. PMID: 16361636.
        View in: PubMed
      191. Hjelmeland AB, Hjelmeland MD, Shi Q, Hart JL, Bigner DD, Wang XF, Kontos CD, Rich J. Loss of phosphatase and tensin homologue increases transforming growth factor beta-mediated invasion with enhanced SMAD3 transcriptional activity. Cancer Res. 2005 Dec 15; 65(24):11276-81. PMID: 16357132.
        View in: PubMed
      192. Rich J, Sathornsumetee S, Keir ST, Kieran MW, Laforme A, Kaipainen A, McLendon RE, Graner MW, Rasheed BK, Wang L, Reardon DA, Ryan AJ, Wheeler C, Dimery I, Bigner DD, Friedman HS. ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors. Clin Cancer Res. 2005 Nov 15; 11(22):8145-57. PMID: 16299247.
        View in: PubMed
      193. Reardon DA, Quinn JA, Rich J, Desjardins A, Vredenburgh J, Gururangan S, Sathornsumetee S, Badruddoja M, McLendon R, Provenzale J, Herndon JE, Dowell JM, Burkart JL, Newton HB, Friedman AH, Friedman HS. Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. Cancer. 2005 Oct 01; 104(7):1478-86. PMID: 16088964.
        View in: PubMed
      194. Rich J, Lee JC. The pathogenesis of Staphylococcus aureus infection in the diabetic NOD mouse. Diabetes. 2005 Oct; 54(10):2904-10. PMID: 16186391.
        View in: PubMed
      195. Quinn JA, Desjardins A, Weingart J, Brem H, Dolan ME, Delaney SM, Vredenburgh J, Rich J, Friedman AH, Reardon DA, Sampson JH, Pegg AE, Moschel RC, Birch R, McLendon RE, Provenzale JM, Gururangan S, Dancey JE, Maxwell J, Tourt-Uhlig S, Herndon JE, Bigner DD, Friedman HS. Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol. 2005 Oct 01; 23(28):7178-87. PMID: 16192602.
        View in: PubMed
      196. Desjardins A, Rich J, Quinn JA, Vredenburgh J, Gururangan S, Sathornsumetee S, Reardon DA, Friedman AH, Bigner DD, Friedman HS. Chemotherapy and novel therapeutic approaches in malignant glioma. Front Biosci. 2005 Sep 01; 10:2645-68. PMID: 15970525.
        View in: PubMed
      197. Rich J, Hans C, Jones B, Iversen ES, McLendon RE, Rasheed BK, Dobra A, Dressman HK, Bigner DD, Nevins JR, West M. Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res. 2005 May 15; 65(10):4051-8. PMID: 15899794.
        View in: PubMed
      198. Dean DE, Tatarek NE, Rich J, Brogdon BG, Powers RH. Human identification from the ankle with pre- and postsurgical radiographs. J Clin Forensic Med. 2005 Feb; 12(1):5-9. PMID: 15763682.
        View in: PubMed
      199. Reardon DA, Quinn JA, Vredenburgh J, Rich J, Gururangan S, Badruddoja M, Herndon JE, Dowell JM, Friedman AH, Friedman HS. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. Cancer. 2005 Jan 15; 103(2):329-38. PMID: 15558802.
        View in: PubMed
      200. Goudar RK, Shi Q, Hjelmeland MD, Keir ST, McLendon RE, Wikstrand CJ, Reese ED, Conrad CA, Traxler P, Lane HA, Reardon DA, Cavenee WK, Wang XF, Bigner DD, Friedman HS, Rich J. Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol Cancer Ther. 2005 Jan; 4(1):101-12. PMID: 15657358.
        View in: PubMed
      201. Shi Q, Bao S, Maxwell JA, Reese ED, Friedman HS, Bigner DD, Wang XF, Rich J. Secreted protein acidic, rich in cysteine (SPARC), mediates cellular survival of gliomas through AKT activation. J Biol Chem. 2004 Dec 10; 279(50):52200-9. PMID: 15469933.
        View in: PubMed
      202. Rich J, Rasheed BK, Yan H. EGFR mutations and sensitivity to gefitinib. N Engl J Med. 2004 Sep 16; 351(12):1260-1; author reply 1260-1. PMID: 15376352.
        View in: PubMed
      203. Hjelmeland MD, Hjelmeland AB, Sathornsumetee S, Reese ED, Herbstreith MH, Laping NJ, Friedman HS, Bigner DD, Wang XF, Rich J. SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility. Mol Cancer Ther. 2004 Jun; 3(6):737-45. PMID: 15210860.
        View in: PubMed
      204. Rich J, Bigner DD. Development of novel targeted therapies in the treatment of malignant glioma. Nat Rev Drug Discov. 2004 May; 3(5):430-46. PMID: 15136790.
        View in: PubMed
      205. Learn CA, Hartzell TL, Wikstrand CJ, Archer GE, Rich J, Friedman AH, Friedman HS, Bigner DD, Sampson JH. Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme. Clin Cancer Res. 2004 May 01; 10(9):3216-24. PMID: 15131063.
        View in: PubMed
      206. Quinn JA, Reardon DA, Friedman AH, Rich J, Sampson JH, Vredenburgh J, Gururangan S, Provenzale JM, Walker A, Schweitzer H, Bigner DD, Tourt-Uhlig S, Herndon JE, Affronti ML, Jackson S, Allen D, Ziegler K, Bohlin C, Lentz C, Friedman HS. Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma. Neuro Oncol. 2004 Apr; 6(2):145-53. PMID: 15134629; PMCID: PMC1871988.
      207. Bos TJ, Cohn SL, Kleinman HK, Murphy-Ulrich JE, Podhajcer OL, Rempel SA, Rich J, Rutka JT, Sage EH, Thompson EW. International Hermelin brain tumor symposium on matricellular proteins in normal and cancer cell-matrix interactions. Matrix Biol. 2004 Apr; 23(1):63-9. PMID: 15230275.
        View in: PubMed
      208. Reardon DA, Quinn JA, Rich J, Gururangan S, Vredenburgh J, Sampson JH, Provenzale JM, Walker A, Badruddoja M, Tourt-Uhlig S, Herndon JE, Dowell JM, Affronti ML, Jackson S, Allen D, Ziegler K, Silverman S, Bohlin C, Friedman AH, Bigner DD, Friedman HS. Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma. Neuro Oncol. 2004 Apr; 6(2):134-44. PMID: 15134628; PMCID: PMC1871982.
      209. Bao S, Ouyang G, Bai X, Huang Z, Ma C, Liu M, Shao R, Anderson RM, Rich J, Wang XF. Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway. Cancer Cell. 2004 Apr; 5(4):329-39. PMID: 15093540.
        View in: PubMed
      210. Rich J, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne KL, Wikstrand CJ, Van Duyn LB, Dancey JE, McLendon RE, Kao JC, Stenzel TT, Ahmed Rasheed BK, Tourt-Uhlig SE, Herndon JE, Vredenburgh JJ, Sampson JH, Friedman AH, Bigner DD, Friedman HS. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol. 2004 Jan 01; 22(1):133-42. PMID: 14638850.
        View in: PubMed
      211. Sampson JH, Akabani G, Archer GE, Bigner DD, Berger MS, Friedman AH, Friedman HS, Herndon JE, Kunwar S, Marcus S, McLendon RE, Paolino A, Penne K, Provenzale J, Quinn J, Reardon DA, Rich J, Stenzel T, Tourt-Uhlig S, Wikstrand C, Wong T, Williams R, Yuan F, Zalutsky MR, Pastan I. Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J Neurooncol. 2003 Oct; 65(1):27-35. PMID: 14649883.
        View in: PubMed
      212. Gururangan S, McLaughlin C, Quinn J, Rich J, Reardon D, Halperin EC, Herndon J, Fuchs H, George T, Provenzale J, Watral M, McLendon RE, Friedman A, Friedman HS, Kurtzberg J, Vredenbergh J, Martin PL. High-dose chemotherapy with autologous stem-cell rescue in children and adults with newly diagnosed pineoblastomas. J Clin Oncol. 2003 Jun 01; 21(11):2187-91. PMID: 12775745.
        View in: PubMed
      213. Rich J, Shi Q, Hjelmeland M, Cummings TJ, Kuan CT, Bigner DD, Counter CM, Wang XF. Bone-related genes expressed in advanced malignancies induce invasion and metastasis in a genetically defined human cancer model. J Biol Chem. 2003 May 02; 278(18):15951-7. PMID: 12590137.
        View in: PubMed
      214. Quinn JA, Reardon DA, Friedman AH, Rich J, Sampson JH, Provenzale JM, McLendon RE, Gururangan S, Bigner DD, Herndon JE, Avgeropoulos N, Finlay J, Tourt-Uhlig S, Affronti ML, Evans B, Stafford-Fox V, Zaknoen S, Friedman HS. Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol. 2003 Feb 15; 21(4):646-51. PMID: 12586801.
        View in: PubMed
      215. Rich J. The role of transforming growth factor-beta in primary brain tumors. Front Biosci. 2003 Jan 01; 8:e245-60. PMID: 12456378.
        View in: PubMed
      216. Rich J, Tatarek NE, Powers RH, Brogdon BG, Lewis BJ, Dean DE. Using pre- and post-surgical foot and ankle radiographs for identification. J Forensic Sci. 2002 Nov; 47(6):1319-22. PMID: 12455656.
        View in: PubMed
      217. Hamad NM, Elconin JH, Karnoub AE, Bai W, Rich J, Abraham RT, Der CJ, Counter CM. Distinct requirements for Ras oncogenesis in human versus mouse cells. Genes Dev. 2002 Aug 15; 16(16):2045-57. PMID: 12183360.
        View in: PubMed
      218. Quinn JA, Pluda J, Dolan ME, Delaney S, Kaplan R, Rich J, Friedman AH, Reardon DA, Sampson JH, Colvin OM, Haglund MM, Pegg AE, Moschel RC, McLendon RE, Provenzale JM, Gururangan S, Tourt-Uhlig S, Herndon JE, Bigner DD, Friedman HS. Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J Clin Oncol. 2002 May 01; 20(9):2277-83. PMID: 11980998.
        View in: PubMed
      219. Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE, Cokgor I, McLendon RE, Pegram CN, Provenzale JM, Quinn JA, Rich J, Regalado LV, Sampson JH, Shafman TD, Wikstrand CJ, Wong TZ, Zhao XG, Zalutsky MR, Bigner DD. Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol. 2002 Mar 01; 20(5):1389-97. PMID: 11870184.
        View in: PubMed
      220. Gururangan S, Cokgor L, Rich J, Edwards S, Affronti ML, Quinn JA, Herndon JE, Provenzale JM, McLendon RE, Tourt-Uhlig S, Sampson JH, Stafford-Fox V, Zaknoen S, Early M, Friedman AH, Friedman HS. Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. Neuro Oncol. 2001 Oct; 3(4):246-50. PMID: 11584894; PMCID: PMC1920622.
      221. Rich J, Guo C, McLendon RE, Bigner DD, Wang XF, Counter CM. A genetically tractable model of human glioma formation. Cancer Res. 2001 May 01; 61(9):3556-60. PMID: 11325817.
        View in: PubMed
      222. Rich J, Borton A, Wang X. Transforming growth factor-beta signaling in cancer. Microsc Res Tech. 2001 Feb 15; 52(4):363-73. PMID: 11170295.
        View in: PubMed
      223. Tielinen L, Manninen M, Puolakkainen P, Kellomäki M, Törmälä P, Rich J, Seppälä J, Rokkanen P. Inability of transforming growth factor-beta 1, combined with a bioabsorbable polymer paste, to promote healing of bone defects in the rat distal femur. Arch Orthop Trauma Surg. 2001; 121(4):191-6. PMID: 11317678.
        View in: PubMed
      224. Friedman HS, Pluda J, Quinn JA, Ewesuedo RB, Long L, Friedman AH, Cokgor I, Colvin OM, Haglund MM, Ashley DM, Rich J, Sampson J, Pegg AE, Moschel RC, McLendon RE, Provenzale JM, Stewart ES, Tourt-Uhlig S, Garcia-Turner AM, Herndon JE, Bigner DD, Dolan ME. Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol. 2000 Oct 15; 18(20):3522-8. PMID: 11032594.
        View in: PubMed
      225. Rich J, Zhang M, Datto MB, Bigner DD, Wang XF. Transforming growth factor-beta-mediated p15(INK4B) induction and growth inhibition in astrocytes is SMAD3-dependent and a pathway prominently altered in human glioma cell lines. J Biol Chem. 1999 Dec 03; 274(49):35053-8. PMID: 10574984.
        View in: PubMed
      226. Friedman HS, Petros WP, Friedman AH, Schaaf LJ, Kerby T, Lawyer J, Parry M, Houghton PJ, Lovell S, Rasheed K, Cloughsey T, Stewart ES, Colvin OM, Provenzale JM, McLendon RE, Bigner DD, Cokgor I, Haglund M, Rich J, Ashley D, Malczyn J, Elfring GL, Miller LL. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol. 1999 May; 17(5):1516-25. PMID: 10334539.
        View in: PubMed
      227. Friedman HS, McLendon RE, Kerby T, Dugan M, Bigner SH, Henry AJ, Ashley DM, Krischer J, Lovell S, Rasheed K, Marchev F, Seman AJ, Cokgor I, Rich J, Stewart E, Colvin OM, Provenzale JM, Bigner DD, Haglund MM, Friedman AH, Modrich PL. DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol. 1998 Dec; 16(12):3851-7. PMID: 9850030.
        View in: PubMed
      228. Friedman HS, Kokkinakis DM, Pluda J, Friedman AH, Cokgor I, Haglund MM, Ashley DM, Rich J, Dolan ME, Pegg AE, Moschel RC, McLendon RE, Kerby T, Herndon JE, Bigner DD, Schold SC. Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma. J Clin Oncol. 1998 Nov; 16(11):3570-5. PMID: 9817277.
        View in: PubMed
      229. Mylonakis E, Rich J, Skolnik PR, De Orchis DF, Flanigan T. Invasive Aspergillus sinusitis in patients with human immunodeficiency virus infection. Report of 2 cases and review. Medicine (Baltimore). 1997 Jul; 76(4):249-55. PMID: 9279331.
        View in: PubMed
      230. Rich J, Elion GB, Wellner D, Colvin OM, Groothuis DR, Hilton JH, Schlageter KE, Bigner DD, Griffith OW, Friedman HS. The effect of L-amino acid oxidase on activity of melphalan against an intracranial xenograft. Cancer Chemother Pharmacol. 1995; 36(5):379-84. PMID: 7634379.
        View in: PubMed
      231. Friedman HS, Dolan ME, Moschel RC, Pegg AE, Felker GM, Rich J, Bigner DD, Schold SC. Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme. J Natl Cancer Inst. 1992 Dec 16; 84(24):1926-31. PMID: 1334154.
        View in: PubMed
      Jeremy's Networks
      Concepts
      Derived automatically from this person's publications.
      _
      Co-Authors
      People in Profiles who have published with this person.
      _
      Similar People
      People who share similar concepts with this person.
      _
      Same Department